Published in Curr Med Chem on January 01, 2006
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Computer-aided quantification of retinal neovascularization. Angiogenesis (2009) 1.50
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther (2007) 1.23
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med (2007) 1.12
Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia (2009) 0.99
Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem (2009) 0.98
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97
Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer (2012) 0.94
The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int J Clin Exp Med (2013) 0.94
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol (2011) 0.93
The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. J Cancer Res Clin Oncol (2012) 0.93
Possible biological and translational significance of mast cells density in colorectal cancer. World J Gastroenterol (2014) 0.92
Nestin(+) tissue-resident multipotent stem cells contribute to tumor progression by differentiating into pericytes and smooth muscle cells resulting in blood vessel remodeling. Front Oncol (2014) 0.88
VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. J Cell Mol Med (2008) 0.88
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. Br J Cancer (2012) 0.86
HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop (2008) 0.84
Mitogen-activated protein 3 kinase 6 mediates angiogenic and tumorigenic effects via vascular endothelial growth factor expression. Am J Pathol (2009) 0.84
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy. Int J Nanomedicine (2014) 0.82
EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett (2008) 0.82
Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clin Exp Metastasis (2011) 0.81
Phage-display selection on tumor histological specimens with laser capture microdissection. J Immunol Methods (2009) 0.80
Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol (2012) 0.80
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol (2014) 0.80
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2008) 0.79
Discovering small molecule ligands of vascular endothelial growth factor that block VEGF-KDR binding using label-free microarray-based assays. Assay Drug Dev Technol (2013) 0.79
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Invest New Drugs (2012) 0.79
Effects of resveratrol on vascular endothelial growth factor expression in osteosarcoma cells and cell proliferation. Oncol Lett (2012) 0.79
Monoclonal antibodies in gynecological cancer: a critical point of view. Clin Dev Immunol (2011) 0.78
Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World J Gastroenterol (2015) 0.78
Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy. Stem Cells Int (2016) 0.77
Updates on the Clinical Trials in Diabetic Macular Edema. Middle East Afr J Ophthalmol (2016) 0.77
First line targeted therapies in breast cancer: focus on bevacizumab. Biologics (2007) 0.76
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer (2016) 0.75
Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am (2015) 0.75
A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther (2016) 0.75
Molecular docking of 1H-pyrazole derivatives to receptor tyrosine kinase and protein kinase for screening potential inhibitors. Bioinformation (2014) 0.75
Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: A case report. Oncol Lett (2016) 0.75
Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting? Int J Ophthalmol (2014) 0.75
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther (2017) 0.75
Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility. BMC Cancer (2016) 0.75
Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis (2012) 0.75
Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. J Ovarian Res (2016) 0.75
Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth. Cancer Sci (2016) 0.75
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.75
Effect of bevacizumab treatment on p-boronophenylalanine distribution in murine tumor. J Radiat Res (2012) 0.75
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. Int J Mol Sci (2017) 0.75
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Sonographic quantitative evaluation of scrotal veins in healthy subjects: normative values and implications for the diagnosis of varicocele. Eur Urol (2006) 2.17
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica (2003) 1.97
Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res (2007) 1.79
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res (2006) 1.72
Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica (2002) 1.69
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res (2007) 1.48
The role of podoplanin in tumor progression and metastasis. Anticancer Res (2008) 1.48
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res (2003) 1.45
Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res (2004) 1.41
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
A portrait of Aristotle as an anatomist: historical article. Clin Anat (2007) 1.40
Mondino de' Liuzzi and his Anothomia: a milestone in the development of modern anatomy. Clin Anat (2006) 1.38
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res (2006) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc Res (2004) 1.35
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
Nerve growth factor as an angiogenic factor. Microvasc Res (2007) 1.32
Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol (2008) 1.30
Analysis of the role of chemokines in angiogenesis. J Immunol Methods (2003) 1.30
Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene. Mol Pharmacol (2005) 1.27
Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat (2004) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia (2003) 1.21
Isolated splenic metastasis from colon cancer. Report of a case. Tumori (2008) 1.19
Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res (2002) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A (2012) 1.15
Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res (2008) 1.14
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
Human peripheral blood eosinophils induce angiogenesis. Int J Biochem Cell Biol (2005) 1.11
Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression. Eur J Cancer (2005) 1.10
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res (2010) 1.09
Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol (2010) 1.09
Piecemeal degranulation as a general secretory mechanism? Anat Rec A Discov Mol Cell Evol Biol (2003) 1.09
In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J (2001) 1.06
Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol (2011) 1.06
Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res (2012) 1.05
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol (2005) 1.05
Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res (2007) 1.05
Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol (2009) 1.05
Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol (2003) 1.04
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol (2005) 1.04
Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett (2008) 1.04
Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol (2009) 1.04
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood (2006) 1.04
Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology (2013) 1.03
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol (2005) 1.03
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer (2004) 1.00
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Morphofunctional aspects of the blood-brain barrier. Curr Drug Metab (2012) 1.00
Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol (2005) 1.00
Long-term changes to in vitro preserved bioengineered human trachea and their implications for decellularized tissues. Biomaterials (2012) 1.00
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep (2010) 0.99
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res (2003) 0.98
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res (2005) 0.98
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev (2008) 0.98
Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol (2013) 0.97
Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol (2006) 0.96
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther (2011) 0.96
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides (2008) 0.96
Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release (2010) 0.96
The chick embryo chorioallantoic membrane as a model to study tumor metastasis. Angiogenesis (2008) 0.95
Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep (2004) 0.95
The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res (2009) 0.95
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer (2009) 0.95
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95
Endothelialization approaches for viable engineered tissues. Angiogenesis (2012) 0.94
Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol (2011) 0.94
Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood (2006) 0.94
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem (2010) 0.94
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther (2008) 0.94
Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc Res Tech (2005) 0.94
Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene (2005) 0.93
Soul, mind, brain: Greek philosophy and the birth of neuroscience. Brain Res Bull (2006) 0.93
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood (2002) 0.93
The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep (2003) 0.93
Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol (2006) 0.93
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther (2005) 0.93
Chorioallantoic membrane for in vivo investigation of tissue-engineered construct biocompatibility. J Biomed Mater Res B Appl Biomater (2012) 0.93
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res (2010) 0.93
Angiogenesis in multiple myeloma. Chem Immunol Allergy (2013) 0.93
Myasthenia gravis and the thymus gland. A historical review. Clin Exp Med (2008) 0.93
Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. Updates Surg (2012) 0.92